A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
about
Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical StudiesVulnerable COPD patients with comorbidities: the role of roflumilast.Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.Roflumilast: a novel treatment for chronic obstructive pulmonary disease.Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.Cost-effectiveness of pharmacotherapy for COPD in ambulatory care: a review.The road not taken: transferability issues in multinational trials.Estimating productivity costs using the friction cost approach in practice: a systematic review.Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.Economic evaluation of a psychological intervention for high distress cancer patients and carers: costs and quality-adjusted life years.Roflumilast: systemic therapy for chronic obstructive pulmonary disease.Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma
P2860
Q28083366-045A280F-2F82-412E-A412-346D8DAD8C93Q34566361-6B8F9B63-7618-45B1-9089-33C41040C293Q35194591-1E879674-EFA2-45B0-B661-A0895CD2C6C4Q37992679-F41B3577-C9F5-4EAC-B1C0-27585A3FD1BCQ37995404-67CE609B-5B60-4FCC-9901-4F28220EF51BQ38063794-C38A7845-819A-4D8A-9B03-DD3AB9BE4033Q38099359-E550E94B-D178-4A79-A383-79619599F69EQ38131747-D73E4D47-F636-4F54-B3B5-F11C8B76B332Q38267181-CC416C60-FA9D-402A-A44F-7B04129F2585Q39020015-EA394409-7327-4FF3-88A2-B2ECCF50B326Q40366351-C2879552-23F0-4F3F-9359-0161CC1E9C08Q43061644-71CB43B1-C16D-452D-9EDC-A2CC86B199FCQ47551310-E3D1FECB-C97D-4A5E-998F-4A73685DA250Q56909272-81EE9255-5E19-492C-A96C-E1837B16777D
P2860
A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A 1-year prospective cost-effe ...... obstructive pulmonary disease.
@en
A 1-year prospective cost-effe ...... obstructive pulmonary disease.
@nl
type
label
A 1-year prospective cost-effe ...... obstructive pulmonary disease.
@en
A 1-year prospective cost-effe ...... obstructive pulmonary disease.
@nl
prefLabel
A 1-year prospective cost-effe ...... obstructive pulmonary disease.
@en
A 1-year prospective cost-effe ...... obstructive pulmonary disease.
@nl
P2093
P2860
P1433
P1476
A 1-year prospective cost-effe ...... obstructive pulmonary disease
@en
P2093
Floortje E van Nooten
Manfred Caeser
Marion Lindemann
Peter M A Calverley
P2860
P304
P356
10.2165/00019053-200725080-00007
P577
2007-01-01T00:00:00Z
P6179
1009015418